Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.43 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.40 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12449102 | 0.87 | IDO1 (0.46) | IDO1CYP3A4EPHX1PYCR1SLC6A2 | |
| SCHEMBL12575211 | 0.86 | SLC6A2 (0.49) | IDO1CYP3A4EPHX1PYCR1SLC6A2 | |
| SCHEMBL2263360 | 0.81 | IDO1 (0.42) | IDO1CYP3A4EPHX1PYCR1SLC6A2 | |
| SCHEMBL12449803 | 0.78 | ALDH1A1 (0.52) | CYP3A4MEN1HTTKMT2A | |
| SCHEMBL9824373 | 0.76 | FSCN1 (0.53) | IDO1CYP3A4FSCN1PYCR1SLC6A2 | |
| SCHEMBL17513270 | 0.75 | TACR1 (0.38) | IDO1CYP3A4MEN1HTTKMT2A | |
| SCHEMBL15003280 | 0.75 | PNMT (0.46) | CYP3A4PYCR1SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL11454882 | 0.74 | PYCR1 (0.45) | IDO1CYP3A4EPHX1PYCR1SLC6A2 | |
| SCHEMBL12638453 | 0.73 | FSCN1 (0.57) | IDO1CYP3A4EPHX1FSCN1SMN1; SMN2 | |
| SCHEMBL12637674 | 0.72 | ROCK1 (0.47) | CYP3A4MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150197496-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-07-16 | — | — | US | disclosed |
| EP-2404907-B1 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2173723-B3 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20140315887-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2014-10-23 | — | — | US | disclosed |
| US-8846683-B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130143865-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8377937-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2173723-B1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110160221-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197496-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | IDO1 1252/4885CYP3A4 1166/4885EPHX1 2576/4885 |
| US-20140315887-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | IDO1 1252/4885CYP3A4 1166/4885EPHX1 2576/4885 |
| US-20130143865-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | IDO1 1252/4885CYP3A4 1166/4885EPHX1 2576/4885 |
| US-20110160221-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | IDO1 1252/4885CYP3A4 1166/4885EPHX1 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.